Trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer: a retrospective study at a tertiary oncology center
AK Patel, R Abhyankar, LK Brais, MS Duh… - The …, 2021 - academic.oup.com
Abstract Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …
patients with refractory metastatic colorectal cancer (mCRC); limited comparative …
Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study.
AK Patel, K Ng, MS Duh, VE Barghout, L Huynh… - 2019 - ascopubs.org
592 Background: FTD/TPI and REG have both demonstrated prolonged survival in refractory
mCRC patients (pts) when compared to placebo but limited comparative effectiveness data …
mCRC patients (pts) when compared to placebo but limited comparative effectiveness data …
Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international …
Background: The oral chemotherapy trifluridine/tipiracil (FTD/TPI or TAS-102) is approved
for treatment of previously treated mCRC patients (pts) beyond the second line, in the same …
for treatment of previously treated mCRC patients (pts) beyond the second line, in the same …
Sequential treatment with trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer patients: an AGEO prospective “Real-World study”
C Coutzac, I Trouilloud, P Artru, J Henriques… - Clinical Colorectal …, 2022 - Elsevier
Introduction Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in
metastatic colorectal cancer (mCRC) patient's refractory to standard therapies. However, it …
metastatic colorectal cancer (mCRC) patient's refractory to standard therapies. However, it …
Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a …
T Moriwaki, S Fukuoka, H Taniguchi… - The …, 2018 - academic.oup.com
Background This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD)
in patients with metastatic colorectal cancer (mCRC) who are refractory to standard …
in patients with metastatic colorectal cancer (mCRC) who are refractory to standard …
Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study.
C Coutzac, I Trouilloud, P Artru, J Henriques, T Masson… - 2020 - ascopubs.org
4036 Background: Regorafenib (R) and trifluridine/tipiracil (T) have proved their efficacy in
patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy …
patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy …
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study in Japan
M Ogata, M Kotaka, T Ogata, Y Hatachi, H Yasui… - PLoS …, 2020 - journals.plos.org
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic
colorectal cancer patients previously treated with standard chemotherapies; therefore, we …
colorectal cancer patients previously treated with standard chemotherapies; therefore, we …
A real-world comparison of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer in the United States
Background: Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the
United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals …
United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals …
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World …
C Signorelli, MA Calegari, M Basso, A Anghelone… - Current …, 2023 - mdpi.com
Background: Patients with refractory mCRC rarely undergo third-line or subsequent
treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) …
treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) …
An observational study of trifluridine/tipiracil-containing regimen versus regorafenib-containing regimen in patients with metastatic colorectal cancer
MC Hsieh, KM Rau, SE Lin, KW Liu, CC Chiu… - Frontiers in …, 2022 - frontiersin.org
Background There are no randomized control trials comparing the efficacy of
trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer (mCRC) …
trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer (mCRC) …